





A**Average liver fat-% to liver volume correlation****B****Average liver fat-% to LV/BW correlation**


Supplementary Figure 1. Rifa-Stea clinical trial. Correlation graphs of A) average liver fat-% to liver volume and B) average liver fat-% to liver volume-to-body weight ratio (LV/BW). No significant correlation can be found in either rifampicin (RIF) or placebo group, * $p < 0.05$.




Supplementary Figure 2. Effect of 4-day PCN treatment on hepatic *Cyp3a11* mRNA level in mPXR re-expressing male and female mice compared to control GFP-groups. No change in *Cyp3a11* expression was observed in the mPXR re-expressing male mice without PCN treatment (NO PCN). M=males, F=females, d=days. Results are presented as mean $\pm$ SD (n=7). ****p<0.0001.



Supplementary Figure 3. HE-staining of the livers from 1- and 4-day PCN-treated male mice. Image taken at 20x magnification. CV=central vein, PV=portal vein.




Supplementary Figure 4. Immunoaffinity-LC-MS/MS analysis of CYP proteins from the livers of 1- and 4-day PCN-treated male mice. In CYP2E1 panel several values exceed the upper detection limit of the machine (>20 fmol/μg) and have therefore been marked with value of 20. M=males, d=days. Results are presented as mean ± SD (n=4). *p<0.05; **p<0.01.




Supplementary Figure 5. Microsphere-based array panel for Beta-catenin profiling from 1- and 4-day PCN-treated mice livers. There are no statistically significant differences between the groups. MFI=median fluorescence intensity, M=males, d=days. Results are presented as mean $\pm$ SD (n=4 for GFP and mPXR, and n=1 for controls).

HIPPO-YAP SIGNALING 1 day males




HIPPO-YAP SIGNALING 4 day males



Supplementary Figure 6. Graphical representation of the effect of mPXR activation on HIPPO-YAP pathway in 1- and 4-day PCN-treated male mice. Statistical significance level $p < 0.05$.

PI3K-AKT-MTOR 1 day males



Supplementary Figure 7. Graphical representation of the effect of mPXR activation on PI3K-AKT-MTOR-pathway in 1-day PCN-treated male mice. Statistical significance level $p < 0.05$.